Lixte's LB-100 Blocks Behavioral Sensitization In Animal Models

Lixte Biotechnology Holdings Inc LIXT has announced additional results from preclinical studies of its lead clinical compound, LB-100, a protein phosphatase 2A (PP2A) inhibitor.
Data showed to reduce behavioral sensitization underlying addiction to methamphetamine.
Related: A Breakthrough in Targeted Cancer Therapy: Lixte Biotechnology Clinical Stage Compound LB-100.
Behavioral sensitization is widely considered a critical neurobiological mechanism in drug addiction.
Studies in animal models have shown that dysregulation in the activity of PP2A could be a factor in diseases of the central nervous system, including drug addiction.
Last month, Lixte commented on LB-100's PP2A inhibition as a potential therapeutic strategy for triple-negative breast cancer.
The announcement was followed by a report that LB-100, combined with another investigational agent, stimulated bone growth in models of dwarfism.
Price Action: LIXT shares are down 0.46% at $2.16 during the market session on the last check Tuesday.